Edgar Filing: Xenon Pharmaceuticals Inc. - Form 4

Xenon Pharmaceuticals Inc.									
Form 4 March 14, 2017									
FORM /				OMB APPROVA	L				
Check this box	COMMISSION	OMB 3235- Number:							
if no longer STATEM	IENT OF CHANGES IN B	ENEFICIAL OW	NEDCUID OF	Expires: Januar	′y 31, 2005				
subject to STATEN Section 16. Form 4 or	IENT OF CHANGES IN B SECURI		NEKSHII UF	Estimated average burden hours per					
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 5 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 30(h) of the Investment Company Act of 1940									
(Print or Type Responses)									
1. Name and Address of Reporting F MORTIMER IAN	Ficker or Trading	Issuer							
	Xenon Pharmaceut		(Check	all applicable)					
(Last) (First) (N	Aiddle) 3. Date of Earliest Tran (Month/Day/Year)	nsaction	Director	10% Owner					
C/O XENON PHARMACEUTICALS INC, 3650 GILMORE WAY	03/13/2017		Officer (give below)						
(Street)	e Original								
BURNABY, A1 V5G 4W8		Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City) (State) ((Zip) Table I - Non-Dep	rivative Securities Acc		or Beneficially Owned	1				
1.Title of 2. Transaction Date Security (Month/Day/Year)	2A. Deemed 3. 4. Execution Date, if TransactionA	. Securities 5 Acquired (A) or 5	5. Amount of 6. Securities Fo	Ownership 7. Nature orm: Direct Indirect	of				
	•	Instr. 3, 4 and 5) C	Owned(I)Following(In	O) or IndirectBeneficiaO)Ownershnstr. 4)(Instr. 4)					
	Code V A	(A) 7 or (Reported Fransaction(s) Instr. 3 and 4)						
Reminder: Report on a separate line	for each class of securities benefic	ially owned directly or	indirectly						
Kenninger: Report on a separate mie	for each class of securities benefic	Persons who resp information contai	ond to the collect						
		required to respon displays a current number.	nd unless the form	ı Č					
Table	e II - Derivative Securities Acqui (e.g., puts, calls, warrants, o								
		4. 5. Number of FransactionDerivative	f 6. Date Exercisal Expiration Date		d Amount of 8 g Securities 1				

Edgar Filing: Xenon Pharmaceuticals Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		ny Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)				
				Code V	(A) (D)) Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 8.4	03/13/2017		А	75,000	<u>(1)</u>	03/12/2027	Common Shares	75,000				
Reporting Owners													
Re	eporting Owner Name / Address			Rela	ationships								
		Director	10% Owner	Officer	Other								
200 - 365			NC		CFO & 0	200							
Signa	tures												
/s/ Joanne Attorney-			03/14/2017										
<u>**</u> Signatu	are of Reporting Per	rson	Date										

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (